Saturday 17 October 2026
Export LUCY’s income statement to Excel — free account
Innovative Eyewear, Inc.
LUCY Healthcare Medical Instruments & Supplies
Innovative Eyewear, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 million, up 62.7% from fiscal 2024. In the quarter to June 2026, revenue grew 74.5%, EPS grew 60.6%, free cash flow grew 9.61% and total debt fell 92.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.79
0.05
−5.95%
Follow LUCY
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 5 | 4 | 4 | — | — |
Altman Z-Score |
(3.75) | 0.97 | (1.61) | 2.14 | — | — |
P/S ratio |
1.50 | 4.50 | 4.79 | 12.37 | 48.32 | 48.32 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.73) | 4.91 | (2.19) | (3.71) | (43.85) | (65.85) |
P/Operating CF |
(2.96) | (3.79) | (4.11) | (7.30) | (70.65) | (70.65) |
Beneish M-Score |
(2.44) | (3.77) | — | — | — | — |
P/B ratio |
0.44 | 0.81 | 0.99 | 2.03 | 0.00 | 0.00 |
Price to Tangible BV |
0.47 | 0.85 | 1.05 | 2.10 | 0.00 | 0.00 |
EV/Sales |
(0.91) | (0.06) | 1.12 | 7.02 | 50.90 | 50.90 |
EV/EBITDA |
0.29 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.33 | 0.02 | (0.22) | (1.44) | (18.70) | (18.70) |
EV/FCF |
0.32 | 0.01 | (0.21) | (1.35) | (17.27) | (17.27) |
Quick Ratio |
6.36 | 10.35 | 7.01 | 6.17 | 0.20 | 0.04 |
Current Ratio |
9.03 | 12.52 | 8.99 | 7.07 | 1.04 | 0.19 |
Net Debt/EBITDA |
0.78 | 0.97 | 0.63 | 0.64 | (0.07) | (0.88) |
Debt/Assets |
0.28% | 0.00% | 0.00% | 1.31% | 35.06% | 284.12% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.02 | 1.39 | (1.08) |
Asset Turnover |
0.27 | 0.20 | 0.21 | 0.24 | 1.33 | 0.00 |
Operating CF/Net income |
0.96 | 0.87 | 0.87 | 0.57 | 0.37 | 0.05 |
Capex/Depreciation |
(1.85) | (3.16) | (2.92) | (6.75) | (15.39) | (0.52) |
Interest Coverage |
— | — | (2,285.17) | (53.01) | (81.35) | (153.06) |
| (83.60%) | (106.00%) | (139.06%) | (268.52%) | 1,868.41% | 0.00% | |
| (75.99%) | (96.74%) | (122.17%) | (206.08%) | (626.77%) | 0.00% | |
ROIC |
(205.50%) | (315.25%) | (337.01%) | (704.56%) | (480.61%) | (2,702.33%) |
Return on Tangible Assets |
(89.82%) | (90.22%) | (129.46%) | (151.10%) | (6,787.66%) | 123.09% |
Average Days of Receivables |
19.50 | 24.07 | 29.52 | 61.02 | 22.93 | 0.00 |
Research and Development Expense of Revenue |
27.25% | 50.07% | 57.46% | 79.52% | 12.49% | 64.74% |
Selling, General and Administrative Expense of Revenue |
307.96% | 438.74% | 514.88% | 735.94% | 457.09% | 822.46% |
Intangible Assets out of Total Assets |
0.06 | 0.05 | 0.05 | 0.03 | 0.11 | 0.33 |
Share Based Compensation of Revenue |
27.73% | 47.35% | 81.28% | 223.39% | 193.27% | 143.16% |
Graham Net Nets |
2.09 | 1.15 | 0.90 | 0.44 | (0.05) | (0.05) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(204.00%) | (127.44%) | (139.29%) | (69.90%) | (11.86%) | (11.86%) |
Free Cash Flow Yield |
(189.86%) | (97.98%) | (109.04%) | (42.20%) | (6.10%) | (6.10%) |
Revenue per Share |
0.67 | 1.09 | 1.88 | 2.02 | 2.63 | 0.39 |
Operating CF per Share |
(1.82) | (4.51) | (9.41) | (9.88) | (4.63) | (0.27) |
Capex per Share |
(0.06) | (0.32) | (0.41) | (0.67) | (0.45) | (0.40) |
Free Cash Flow per Share |
(1.88) | (4.82) | (9.81) | (10.55) | (5.08) | (0.67) |
Cash per Share |
1.63 | 5.03 | 6.99 | 11.00 | 0.30 | 0.18 |
Shareholders Equity per Share |
2.27 | 6.08 | 9.07 | 12.33 | 0.79 | (3.75) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.27 | 6.08 | 9.07 | 12.33 | 0.79 | (3.75) |
Free Cash Flow |
(7.52) | (7.21) | (6.02) | (3.44) | (1.33) | (0.10) |
Working Capital |
8.39 | 8.50 | 4.99 | 3.64 | 0.03 | (0.62) |
Capital Expenditures |
(0.25) | (0.47) | (0.25) | (0.22) | (0.12) | (0.06) |
Net Current Asset Value |
8.36 | 8.50 | 4.96 | 3.58 | 0.03 | (0.62) |
EV/EBIT |
0.29 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.09 | 0.29 | 0.22 | 0.33 | 0.17 | 1.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
2.19 | 1.39 | 0.55 | 0.27 | 0.38 | 0.00 |
Cash ROIC |
(48.22%) | (43.39%) | (61.10%) | (44.87%) | (231.29%) | (138.49%) |
Accounts Receivable Turnover |
21.29 | 16.27 | 11.33 | 8.59 | 0.00 | 0.00 |
Accounts Payable Turnover |
2.50 | 2.23 | 2.97 | 3.23 | 4.96 | 0.00 |
Inventory Turnover |
1.22 | 1.35 | 2.21 | 2.26 | 2.52 | 0.00 |
Average Days of Payables |
171.75 | 177.92 | 167.03 | 140.53 | 112.45 | 252.50 |
Days of Inventory on Hand |
380.58 | 322.65 | 245.90 | 149.09 | 228.93 | 441.14 |
Average Receivables |
0.13 | 0.10 | 0.10 | 0.08 | — | — |
Average Payables |
0.84 | 0.64 | 0.43 | 0.22 | 0.11 | — |
Average Inventory |
1.72 | 1.06 | 0.57 | 0.32 | 0.22 | — |
Average Assets |
9.99 | 8.03 | 5.45 | 2.76 | 0.52 | — |
Average Common Equity |
9.08 | 7.33 | 4.79 | 2.12 | (0.17) | — |
Columns are period end dates